34 results on '"Launonen, Aino"'
Search Results
2. Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study
3. Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
4. Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies
5. Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation
6. ABCL-101 Cost-Effectiveness of Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
7. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
8. Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX Study
9. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
10. Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study
11. Poster: ABCL-101 Cost-Effectiveness of Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
12. Oral Abstract: ABCL-101 Cost-Effectiveness of Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
13. Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
14. Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
15. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women
16. Exploring the Impact of Diffuse Large B-Cell Lymphoma (International Prognostic Index [IPI] 2-5) on Clinical and Patient-Relevant Outcomes in the Context of a Clinical Trial
17. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
18. Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
19. Abstract PO-58: Obinutuzumab plus chemotherapy is cost effective versus rituximab biosimilars plus chemotherapy for previously untreated follicular lymphoma patients
20. The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany
21. IBCL-199: Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma
22. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
23. Poster Board #-Session: P95-I AEB071 Pharmacokinetics: Effect of Hepatic Impairment and Consequent Changes in Serum Protein Concentrations.: Abstract# 752
24. Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study
25. Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study
26. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
27. No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study
28. A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial
29. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
30. Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL) in the GALLIUM Study
31. Use of the Levonorgestrel-Releasing Intrauterine System and Breast Cancer
32. Use of the Levonorgestrel-Releasing Intrauterine System and Breast Cancer
33. In Reply: Use of the Levonorgestrel-Releasing Intrauterine System and Breast Cancer.
34. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.